Epithelial ovarian cancer

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 26, Issue 3, 2012, Pages 337-345

  Ng, Joseph S ^a,b   Low, Jeffrey J H ^a,b   Ilancheran, A ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b Singapore Cancer Institute   (Singapore)

Author keywords

congenital anomalies; epithelial ovarian cancer; fertility preservation; intraperitoneal chemotherapy; live births; ovarian cryopreservation

Indexed keywords

ALKYLATING AGENT; ORAL CONTRACEPTIVE AGENT; PLATINUM; TAXANE DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CONGENITAL MALFORMATION; CRYOPRESERVATION; CYTOREDUCTIVE SURGERY; EPITHELIAL OVARY CANCER; HISTOPATHOLOGY; HUMAN; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REPRODUCTIVE PROCEDURES; TREATMENT INDICATION; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; CRYOPRESERVATION; FEMALE; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGAN SPARING TREATMENTS; OVARIAN NEOPLASMS; OVARY;

EID: 84860217976     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2011.12.005     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide. IARC Cancerbase No,10 [Internet] Lyon, France: International Agency for Research on Cancer, 2010; http://globocan.iarc.fr.
2. K.D. Steffensen, M. Waldstrom, and A. Grove Improved classification of epithelial ovarian cancer: results of three Danish cohorts Int J Gynecol Cancer 21 2011 1592 1600
3. N. Liu, X. Wang, and X. Sheng 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis Curr Opin Obstet Gynecol 23 2011 19 23
4. D.J. Gallagher, J.A. Konner, and K.M. Bell-McGuinn Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity Ann Oncol 22 2011 1127 1132
5. S.C. Plaxe, P.S. Braly, and J.L. Freddo Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer Obstet Gynecol 81 1993 651 654 (Pubitemid 23137228)
6. M. Rodriguez, H.N. Nguyen, and H.E. Averette National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age Cancer 73 1994 1245 1250
7. H. Smedley, and K. Sikora Age as a prognostic factor in epithe- lial ovarian carcinoma Br J Obstet Gynaecol 92 1985 839 842 (Pubitemid 16172055)
8. K.D. Swenerton, T.G. Hislop, and J. Spinelli Ovarian carcinoma: a multivariate analysis of prognostic factors Obstet Gynecol 65 1985 264 270 (Pubitemid 15166989)
9. H. Kajiyama, K. Shibata, and M. Mizuno Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery Br J Cancer 105 2011 1288 1294
10. P. Morice, D. Denschlag, and A. Rodolakis Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors Int J Gynecol Cancer 21 2011 951 963
11. T. Thigpen, M.F. Brady, and G.A. Omura Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience Cancer 71 2 Suppl. 1993 606 614
12. L.R. Duska, Y.C. Chang, and C.E. Flynn Epithelial ovarian carcinoma in the reproductive age group Cancer 85 1999 2623 2629 (Pubitemid 29272749)
13. J. Hu, L.R. Zhu, and Z.Q. Liang Clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma J Zhejiang Univ Sci B 12 2011 787 795
14. J.Y. Park, D.Y. Kim, and D.S. Suh Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes Gynecol Oncol 110 2008 345 353
15. A. Pereira, J.F. Magrina, and P.M. Magtibay The impact of peritoneal metastases in epithelial ovarian cancer with positive nodes Int J Gynecol Cancer 21 2011 1375 1379
16. J.O. Schorge, L.A. Garrett, and A. Goodman Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology 25 2011 928 934
17. A. Elattar, A. Bryant, and B.A. Winter-Roach Optimal primary surgical treatment for advanced epithelial ovarian cancer Cochrane Database Syst Rev 10 2011 CD007565
18. E.I. Braicu, J. Sehouli, and R. Richter Primary versus secondary cytoreduction for epithelial ovarian cancer: A paired analysis of tumour pattern and surgical outcome Eur J Cancer 2011 Jul 12 [Epub ahead of print]
19. F. Melica, S. Chiodi, and P.M. Cristoforoni Reductive surgery and ovarian function in the human-can reductive ovarian surgery in reproductive age negatively influence fertility and age at onset of menopause? Int J Fertil Menopausal Stud 40 1995 79 85
20. D. Weinstein, and W.Z. Polishuk The role of wedge resection of the ovary as a cause for mechanical sterility Surg Gynecol Obstet 141 1975 417 418
21. P. Morice, S. Camatte, and J. El Hassan Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors Fertil Steril 75 2001 92 96 (Pubitemid 32041230)
22. C. Brown, J. Hyman, and L. Almadrones Conservative surgical management of early epithelial ovarian cancer (EOC) Proc ASCO 14 1995 766
23. A.P. Heintz, F. Odicino, and P. Maisonneuve Carcinoma of the ovary Int J Gynaecol Obstet 83 Suppl. 1 2003 135 166 (Pubitemid 39658498)
24. H.L. Kottmeier Surgical management-conservative surgery F. Gentil, A.C. Junqueria, Ovarian cancer 2nd ed. 1968 Springer Verlag New York 156 158
25. Y.Y. Lee, T.J. Kim, and M.J. Kim Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis Gynecol Oncol 122 2011 541 547
26. J.D. Wright, M. Shah, and L. Mathew Fertility preservation in young women with epithelial ovarian cancer Cancer 115 2009 4118 4126
27. W.P. McGuire, W.J. Hoskins, and M.F. Brady A phase I trial comparing cisplatin/cytoxan and cisplatin/paclitaxel in advanced ovarian cancer [abstract 808] Proc Am Soc Clin Oncol 12 1993 255
28. W.P. McGuire, W.J. Hoskins, and M.F. Brady Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin [abstract 771] Proc Am Soc Clin Oncol 14 1995 771
29. W.P. McGuire, J. Hoskins, and M.F. Brady Assessment of dose-intensive therapy in sub-optimally debulked ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 13 1995 1589 1599
30. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stageIII and stageIV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
31. F.M. Muggia, P.S. Braly, and M.F. Brady Phase I of cisplatin or paclitaxel versus the combination in suboptimal stage III and IV epithelial ovarian cancer: Gynecologic Oncology Group (GOG) study [abstract 1257] Proc Am Soc Clin Oncol 16 1997
32. Muggia FM, Braly PS, Brady MF, et-al. Phase I comparison of single agents, cisplatin or paclitaxel versus the combination in sub-optimal stageIII and stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. (submitted); 1998.
33. D.K. Armstrong, B. Bundy, and L. Wenzel Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
34. J.M. Fauci, J.M. Whitworth, and K.E. Schneider Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer Gynecol Oncol 122 2011 532 535
35. A.C. Schlaerth, D.S. Chi, and E.A. Poynor Long-term survival after fertility-sparing surgery for epithelial ovarian cancer Int J Gynecol Cancer 19 2009 1199 1204
36. N. Colombo, S. Chiari, and A. Maggioni Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy Gynecol Oncol 55 1994 S47 S51
37. G. Zanetta, S. Chiari, and S. Rota Conservative surgery for stage I ovarian carcinoma in women of childbearing age Br J Obstet Gynaecol 104 1997 1030 1035 (Pubitemid 27400184)
38. F. Raspagliesi, R. Fontanelli, and D. Paladini Conservative surgery in high-risk epithelial ovarian carcinoma J Am Coll Surg 185 1997 457 460 (Pubitemid 27475444)
39. P. Morice, F. Wicart-Poque, and A. Rey Results of conservative treatment in epithelial ovarian carcinoma Cancer 92 2001 2412 2418 (Pubitemid 33029087)
40. J.M. Schilder, A.M. Thompson, and P.D. DePriest Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy Gynecol Oncol 87 2002 1 7 (Pubitemid 36027095)
41. P. Morice, E. Leblanc, and A. Rey Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Societe Francaise d'Oncologie Gynecologique) Hum Reprod 20 2005 1379 1385 (Pubitemid 40790267)
42. C. Borgfeldt, C. Iosif, and A. Masback Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer Eur J Obstet Gynecol Reprod Biol 134 2007 110 114 (Pubitemid 47332804)
43. R.B. Ness, J.A. Grisso, and J. Klapper Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions Am J Epidemiol 152 2000 233 241 (Pubitemid 30640246)
44. K.A. Rosenblatt, D.B. Thomas, and E.A. Noonan High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives Eur J Cancer 28A 1992 1872 1876
45. C.L. Robbins, M.K. Whiteman, and S.D. Hillis Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis Cancer Epidemiol Biomarkers Prev 18 2009 2035 2041
46. I. Benjamin, M.A. Morgan, and S.C. Rubin Occult bilateral involvement in stage I epithelial ovarian cancer Gynecol Oncol 72 1999 288 291 (Pubitemid 29118183)
47. E.W. Munnell Is conservative therapy ever justified in stage I (IA) cancer of the ovary? Am J Obstet Gynecol 103 1969 641 653